BMS, Janssen’s milvexian gets FDA fast track status for three indications
The fast track status for the investigational, oral factor XIa (FXIa) inhibitor (antithrombotic) has been granted in ischemic…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
26 May 23
The fast track status for the investigational, oral factor XIa (FXIa) inhibitor (antithrombotic) has been granted in ischemic…
26 May 23
Continuous Artificial Intelligence (AI) and software updates will be provided by GE HealthCare’s Smart Subscription, a service to…
26 May 23
IBSA, which has made innovation one of its pillars, partnered with InSilicoTrials with the objective of evaluating the…
25 May 23
Yuflyma is now approved to treat eight conditions, including juvenile idiopathic arthritis, rheumatoid arthritis, psoriatic arthritis, Crohn’s disease,…
25 May 23
Under the agreement, Advanz will be responsible for the registration and commercialisation of the candidates in Europe and…
25 May 23
Under the terms of the transaction, Pyxis Oncology expects to issue around 4.4 million shares of its common…
25 May 23
Under the terms of the license agreement, UCB will utilize ClearPoint Neuro’s proprietary technology and services in connection…
25 May 23
The agreement gives Adalvo exclusive rights to register, commercialise and distribute Mellozzan in these countries
24 May 23
Managed by the Foundation for the National Institutes of Health (FNIH), the consortium aims to accelerate the process…
24 May 23
Danyelza is said to be a recombinant humanised, monoclonal antibody that targets the ganglioside GD2, highly expressed in…